http://hl7.org/fhir/uv/ebm/Evidence/557357
type: Evidence
node role: treeRoot
id:
  v: 557357
meta:
  version id:
    v: 1
  last updated:
    v: 2026-04-08T13:56:39.431Z
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/comparator-only-evidence
    l: comparator-only-evidence
language:
  v: en
text:
  status:
    v: extensions
  div:
    v: Generated Narrative: Evidence 557357 version: 1; Last updated: 2026-04-08 13:56:39+0000 Profile: ComparatorOnlyEvidence ArtifactPublicationStatus: Active url: https://fevir.net/resources/Evidence/557357 identifier: FEvIR Object Identifier/557357, outcomeId/313960, picoId/85798, sectionId/73215 name: End_stage_kidney_disease_Comparator_Evidence_from_MAGICapp_313960 title: MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes citeAs: MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557357. Revised 2026-04-08. Available at: https://fevir.net/resources/Evidence/557357. Computable resource at: https://fevir.net/resources/Evidence/557357#json. status: Active author: Computable Publishing®: MAGIC-to-FEvIR Converter: publisher: Computable Publishing LLC contact: support@computablepublishing.com UseContexts - Code Value[x] * Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ComparatorOnlyEvidence copyright: https://creativecommons.org/licenses/by-nc-sa/4.0/ RelatesTos - Type Target[x] * Part Of MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report) description: This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide. note: Defined as a GFR below 45 or a GFR below 70 AND macroalbuminuria (ACR > 200 mg/g); derived from RECODe (https://sanjaybasu.shinyapps.io/recode/). variableDefinition description: Adults with type 2 diabetes -- GLP-1 RA variableRole: Population observed: GLP-1 RA Group in Adults with type 2 diabetes variableDefinition description: End-stage kidney disease var…
extension:
  url:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status
    l: artifact-publication-status
  value: CodeableConcept
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/cited-artifact-status-type
        l: cited-artifact-status-type
      code:
        v: active
      display:
        v: Active
url:
  v: https://fevir.net/resources/Evidence/557357
  l: https://fevir.net/resources/Evidence/557357
identifier:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/v2-0203
        l: v2-0203
      code:
        v: ACSN
      display:
        v: Accession ID
    text:
      v: FEvIR Object Identifier
  system:
    v: https://fevir.net/FOI
    l: FOI
  value:
    v: 557357
  assigner:
    display:
      v: Computable Publishing LLC
identifier:
  type:
    text:
      v: outcomeId
  system:
    v: https://app.magicapp.org/#/guidelines
    l: guidelines
  value:
    v: 313960
identifier:
  type:
    text:
      v: picoId
  system:
    v: https://app.magicapp.org/#/guidelines
    l: guidelines
  value:
    v: 85798
identifier:
  type:
    text:
      v: sectionId
  system:
    v: https://app.magicapp.org/#/guidelines
    l: guidelines
  value:
    v: 73215
name:
  v: End_stage_kidney_disease_Comparator_Evidence_from_MAGICapp_313960
title:
  v: MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes
cite as:
  v: MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557357. Revised 2026-04-08. Available at: https://fevir.net/resources/Evidence/557357. Computable resource at: https://fevir.net/resources/Evidence/557357#json.
status:
  v: active
author:
  name:
    v: Computable Publishing®: MAGIC-to-FEvIR Converter
publisher:
  v: Computable Publishing LLC
contact:
  telecom:
    system:
      v: email
use context:
  code:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: evidence-communication
    display:
      v: Evidence Communication
  value: CodeableConcept
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: ComparatorOnlyEvidence
      display:
        v: ComparatorOnlyEvidence
copyright:
  v: https://creativecommons.org/licenses/by-nc-sa/4.0/
relates to:
  type:
    v: part-of
  target: Reference
    type:
      v: Composition
      l: Composition
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-conversion-report
    display:
      v: MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes
description:
  v: This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.
note:
  text:
    v: Defined as a GFR below 45 or a GFR below 70 AND macroalbuminuria (ACR > 200 mg/g); derived from RECODe (https://sanjaybasu.shinyapps.io/recode/).
variable definition:
  description:
    v: Adults with type 2 diabetes -- GLP-1 RA
  variable role:
    v: population
  observed:
    l: http://hl7.org/fhir/uv/ebm/Group/557341
    reference:
      v: Group/557341
    type:
      v: Group
      l: Group
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-comparator-group-MAGIC-5288-j1Wqrn-compa-85798
    display:
      v: GLP-1 RA Group in Adults with type 2 diabetes
variable definition:
  description:
    v: End-stage kidney disease
  variable role:
    v: outcome
  observed:
    l: http://hl7.org/fhir/uv/ebm/EvidenceVariable/236965
    reference:
      v: EvidenceVariable/236965
    type:
      v: EvidenceVariable
      l: EvidenceVariable
    identifier:
      system:
        v: https://fevir.net/FLI
        l: FLI
      value:
        v: MAGIC-5288-j1Wqrn-313960
    display:
      v: End-stage kidney disease
synthesis type:
  text:
    v: NOTSET
study design:
  text:
    v: NO_STUDY
statistic:
  description:
    v: Risk 11.9%
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000607
      display:
        v: proportion
  quantity:
    value:
      v: 0.119

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC

v: FEvIR Linking Identifier

v: Computable Publishing LLC